摘要
目的:探讨T细胞非霍奇金淋巴瘤(NHL)Ki-67表达及其临床意义。方法:回顾性分析天津医科大学附属肿瘤医院2000年1月～2007年12月。首诊初治T细胞NHL患者78例。治疗采用标准的CHOP、BACOP或CHOP-E方案,T、Ⅱ期患者联合放疗。记录每位患者治疗前的年龄、性别、病理类型、临床分期、ECOG评分、最大肿瘤直径、结外受累部位数、有无B症状、LDH水平、β2MC水平、国际预后指数(IPI)、治疗方案、治疗效果、无进展生存期(PFS)及总生存期(OS)。应用免疫组化方法检测Ki-67的表达情况。应用SPSS 16.0软件进行统计学分析,探讨Ki-67表达与各临床因素之间的关系。结果:Ki-67低表达32例,高表达46例。Ⅰ、Ⅱ期与Ⅲ、Ⅳ期患者之间,最大肿瘤直径≤5cm与>5cm患者之间,LDH水平正常与升高患者之间的Ki-67表达水平有统计学差异(P<0.05)。Ki-67表达水平与其它临床因素之间无统计学差异。Ki-67高表达患者的化疗有效率为78.3%,低表达患者为68.8%,两者之间无统计学差异(P=0.344)。Ki-67低表达患者的PFS及OS较高表达患者长,并且有统计学差异(分别为P=0.036和P=0.029)。多因素分析表明Ki-67是影响PFS及OS的独立预后因素。结论:Ki-67表达水平是T细胞NHL重要的预后因素,是对IPI的重要补充,两者相结合对预测患者的病情发展、制定个体化治疗策略有重要意义。
Objective： To analyze the expression and clinical significance of Ki-67 in T-cell non-Hodgkin lymphoma （NHL）. Methods： Data from 78 patients with untreated T-cell NHL seen in our hospital in the past 8 years were reviewed. All of the diagnoses were confirmed by at least two pathologists. Chemotherapy （CHOP or BACOP or CHOP-E） with standard dosage was administered to every patient. Patients with stage Ⅰ or Ⅱ disease received concurrent radiotherapy. Patient age, gender, pathological type, clinical staging, ECOG per-formance status, maximum diameter of tumor, number of tumor sites excluding lymphoid nodules, presence of B symptoms, LDH level, β2MG levl, international prognostic index （IPI）, method of treatment, response to chemotherapy, progression-free survival （PFS） and overall survival （OS） were recorded. The expression of Ki-67 was determined using immunohistochemistry. The relationship between the expression of Ki-67 and the clinical factors was analyzed using SPSS 16.0. Results： There were 32 patients with low expression of Ki-67 and 46 patients with high expression of Ki-67. The expression of Ki-67 was significantly different among patients of stage Ⅰ, Ⅱ, Ⅲ and Ⅳ. The expression of Ki-67 in patients with a maximum tumor diameter less than or equal to 5cm was significantly different than the expression found in patients with a maximum tumor diameter greater than 5cm. A significant difference was found in Ki-67 expression between patients with a normal LDH level and those with an abnormal LDH level. The response rate to chemotherapy was 78.3% in patients with high Ki-67 expression and 68.8% in patients with low Ki-67 expression, with no significant difference detected between the two groups （P=0.344）. Patients with low Ki-67 expression had longer PFS （P=0.036） and OS （P=0.029） than patients with high Ki-67 expression. Multivariate analysis confirmed that Ki-67 was an independent prognostic factor related to PFS and OS. Conclusion： Ki-67 protein expression le
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2009年第11期644-647,共4页
Chinese Journal of Clinical Oncology
基金
教育部留学回国人员科研启动基金资助(编号:教外司留2008-101号)
